Oct 14,2019

Senseonics Announces a Positive Coverage Decision for Eversense CGM from Health Care Service Corporation

Senseonics Holdings announced that Health Care Service Corporation (HCSC) - Blue Cross Blue Shield is now providing coverage for the Eversense CGM System, effective October 15, 2019. Health Care Service Corporation, a Mutual Legal Reserve Company (HCSC), and an Independent Licensee of the Blue Cross and Blue Shield Association, is the fourth largest health insurer in the United States, operating as Blue Cross and Blue Shield Plans in Illinois, Montana, New Mexico, Oklahoma and Texas. 

COLLABORATION COLLABORATION

#insurance

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 18,2020

Senseonics Announces a Positive Coverage Decision for Eversense CGM from Cigna

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Cigna is now providing coverage for the Eversense® CGM System, effective February 15, 2020. This most recent coverage decision – in addition to Aetna, Humana, HCSC Blue Cross Blue Shield and other health insurance providers – adds to the growing list of payers enabling their members to benefit clinically from the long-term Eversense CGM System.

COLLABORATION PARTNERSHIP

#insurance

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 19,2021

Senseonics Announces a Positive Coverage Decision for Eversense CGM from EmblemHealth

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, announced today that EmblemHealth is now providing coverage for the Eversense® CGM System, effective immediately. EmblemHealth of New York, New Jersey and Connecticut has added coverage for Eversense in their 2021 CGM policy which expands access to approximately 2.9 million residents of these three states.

COLLABORATION PARTNERSHIP

#insurance

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 25,2018

Roche advances its open diabetes management ecosystem by integrating CGM data from Sensonics

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has signed a non-exclusive data integration agreement with Senseonics Incorporated, expanding its partnership. Under the terms of the agreement, both partners aim to implement the next step in data integration of the long-term Eversense Continuous Glucose Monitoring (CGM) system with Roche's suite of digital diabetes management solutions. This integration will allow for the real-time CGM data to be synchronised so Eversense users and their physicians will be able to review glucose values as well as related data online and on their mobile phones e.g. via the mySugr app or Accu-Chek Smart Pix. The initial data integration is planned to be available to users beginning 2019.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 10,2018

Medtronic Receives Health Canada Licence For The First Insulin Pump System That Automatically Adjusts Basal Insulin For People Living with Type 1 Diabetes

Medtronic of Canada Ltd., a subsidiary of Medtronic plc (NYSE: MDT), today announced it has received a licence from Health Canada for the MiniMed™ 670G system — the first insulin pump system in Canada that helps to stabilize glucose levels 24 hours a day by automatically adjusting basal insulin delivery based on real-time insulin needs. The MiniMed 670G system combines the company's most advanced SmartGuard™ algorithm and most accurate2 continuous glucose monitor (CGM), the Guardian™ Sensor 3, to provide simplified diabetes management for Canadians seven years of age and older living with type 1 diabetes.

PRODUCT

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 26,2020

The Health Transformation Alliance and Welltok Select Livongo as First Marketplace Partner

To streamline the selection, contracting and implementation process, the Health Transformation Alliance (HTA) and Welltok, its consumer engagement platform of choice, are creating a curated marketplace of these programs on behalf of the over 50 HTA Member/Owners across the nation. Programs selected to be in the marketplace will be integrated into Welltok's consumer engagement platform. The platform serves as the single destination for employees to access relevant health and wellbeing programs, as well as incentives that their employer may offer for participation.

COLLABORATION PARTNERSHIP

#product & service

#coaching

#cgm

#bgm

View Analyst & Ambassador Comments
Go to original news
Nov 23,2020

Tandem Diabetes Care Extended Partnership with Dexcom

On November 20, 2020, Tandem Diabetes Care, Inc. entered into a Development Agreement and a Commercialization Agreement with DexCom, Inc.. Previously, the Company and DexCom had entered into Development Agreements dated June 4, 2015 that facilitated integration of the Company’s earlier generation insulin pump products with DexCom’s G5 and G6 CGM devices. The New Agreements allow for the continuation of the Company’s and DexCom’s development and collaboration activities that enable the integration of the Company’s insulin pump products with DexCom’s CGM devices. The New Agreements build upon this collaborative relationship, serving to integrate the Company’s current and future generation insulin pump products with DexCom’s G6 and G7 CGM devices.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Sep 20,2022

Insulet Announces CE Mark Approval for Omnipod® 5 Automated Insulin Delivery System

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received CE marking under the European Medical Device Regulation for its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes.

REGULATORY CE MARK

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 20,2022

Insulet wins CE Mark for Omnipod 5 for children 2 and up

Insulet can now market Omnipod 5 in Europe for individuals 2 years and older with type 1 diabetes. Acton, Massachusetts–based Insulet said it represents the first CE-marked tubeless hybrid closed loop system

REGULATORY CE MARK

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 20,2022

Study says Abbott FreeStyle Libre reduces rate of hospitalization

The RELIEF study evaluated Abbott’s FreeStyle Libre continuous glucose monitoring (CGM). The findings included the significant reduction of the rate of hospitalizations due to acute diabetes events (ADEs). This study evaluated people living with type 2 diabetes on once-daily (basal) insulin therapy.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM